Medscape September 3, 2024
(Reuters) -The U.S. government’s first-ever negotiated prices for prescription drugs are still on average more than double, and in some cases five times, what drugmakers have agreed to in four other high-income countries, a Reuters review has found.
The U.S. Medicare health plan, which covers more than 67 million people, recently unveiled new maximum prices for the first 10 high-cost medicines negotiated under the Biden Administration’s Inflation Reduction Act.
This is the first time Medicare has disclosed actual drug prices, which are largely hidden behind a complicated U.S. system of rebates and discounts. The lower prices will result in savings of $6 billion in 2026, the first year they take effect, Medicare said.
A Reuters review of publicly available maximum...
Today's Sponsors
Today's Sponsor